United Kingdom

People: Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

26 Apr 2019
Change (% chg)

$0.22 (+1.10%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Owen, Michael 

Dr. Michael John Owen has been Independent Director at Zealand Pharma A/S since 2012. Michael J. Owen is co-founder and was CSO at Kymab Ltd. (UK). Before joining Kymab, he had several leading positions at GlaxoSmithKline, latterly as SVP and head of biopharmaceuticals research. Prior to joining GSK in 2001, he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years of research experience with a focus on the immune system. He has more than 150 publications and membership of the European Molecular Biology Organization and Fellowship of the Academy of Medical Sciences. He is Member of the board of Blink Biomedical SAS, Avacta Group plc, GammaDelta Therapeutics, Glythera Ltd and ReNeuron Group plc. Moreover, he is advisor to CRT Pioneer Fund LP and Chairman of the Board of Ossianix Inc. He holds Doctorate in Philosophy degree in Biochemistry (Amino and Acid Transport in Trypanosomes) from Cambridge University and Bachelor of Arts degree in Biochemistry from Keble College, Oxford University.

Basic Compensation

Total Annual Compensation, DKK 300,000
Restricted Stock Award, DKK --
Long-Term Incentive Plans, DKK --
All Other, DKK --
Fiscal Year Total, DKK 300,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --